Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

CD20 antibody (Membrane-Spanning 4-Domains, Subfamily A, Member 1) Primary Antibody

MS4A1 Reactivity: Human BR, ELISA, FACS, IP, WB Host: CHO Cells Monoclonal Obinutuzumab unconjugated
Catalog No. ABIN6731001
$360.00
Plus shipping costs $45.00
100 μL
local_shipping Shipping to: United States
Delivery in 7 to 8 Business Days
  • Target
    CD20 (MS4A1)
    Antibody Type
    Recombinant Antibody
    Reactivity
    • 347
    • 75
    • 24
    • 13
    • 12
    • 7
    • 6
    • 3
    • 2
    • 2
    • 2
    • 2
    • 1
    Human
    Host
    • 234
    • 127
    • 7
    • 4
    • 2
    • 2
    • 1
    CHO Cells
    Clonality
    • 266
    • 106
    • 3
    Monoclonal
    Conjugate
    • 128
    • 24
    • 23
    • 21
    • 15
    • 9
    • 8
    • 7
    • 6
    • 6
    • 6
    • 6
    • 6
    • 6
    • 6
    • 6
    • 6
    • 6
    • 6
    • 6
    • 5
    • 4
    • 4
    • 4
    • 4
    • 4
    • 3
    • 3
    • 3
    • 3
    • 3
    • 3
    • 3
    • 3
    • 2
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    This CD20 antibody is un-conjugated
    Application
    • 283
    • 125
    • 83
    • 66
    • 66
    • 45
    • 39
    • 30
    • 27
    • 18
    • 14
    • 13
    • 13
    • 13
    • 9
    • 4
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    Blocking Reagent (BR), ELISA, Flow Cytometry (FACS), Immunoprecipitation (IP), Western Blotting (WB)
    Purpose
    Obinutuzumab is a recombinant monoclonal humanised and glycoengineered Type II anti-CD20 antibody of the IgG1 isotype
    Specificity
    "Obinutuzumab is a recombinant monoclonal humanised and glycoengineered Type II anti-CD20 antibody of the IgG1 isotype"
    Characteristics
    "This is a therapeutic antibody derived from Gazyvaro and designed for research purposes.Obinutuzumab, the active ingredient of Gazyvaro, is a recombinant monoclonal humanised and glycoengineered Type II anti-CD20 antibody of the IgG1 isotype." Obinutuzumab is a recombinant monoclonal humanised and glycoengineered Type II anti-CD20 antibody of the IgG1 isotype. It specifically targets the extracellular loop of the CD20 transmembrane antigen on the surface of non-malignant and malignant pre-B and mature B-lymphocytes, but not on haematopoietic stem cells, pro-B-cells, normal plasma cells or other normal tissue. Glycoengineering of the Fc part of obinutuzumab results in higher affinity for FcɣRIII receptors on immune effector cells such as natural killer (NK) cells, macrophages and monocytes as compared to nonglycoengineered antibodies.
    In nonclinical studies, obinutuzumab induces direct cell death and mediates antibody dependent cellular cytotoxicity (ADCC) and antibody dependent cellular phagocytosis (ADCP) through recruitment of FcɣRIII positive immune effector cells. In addition, in vivo, obinutuzumab mediates a low degree of complement dependent cytotoxicity (CDC). Compared to Type I antibodies, obinutuzumab, a Type II antibody, is characterised by an enhanced direct cell death induction with a concomitant reduction in CDC at an equivalent dose. Obinutuzumab, as a glycoengineered antibody, is characterised by enhanced antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP) compared to non-glycoengineered antibodies at an equivalent dose. In animal models obinutuzumab mediates potent B-cell depletion and antitumour efficacy.
    Purification
    The commercial therapeutic mAb was diluted with sterile PBS to a final 1 mg/ml.  (original drug Gazyvaro 1000 was diluted 1:25)
    Sterility
    Sterile
    Clone
    Obinutuzumab
    Isotype
    IgG1
  • Application Notes
    Optimal dilution for a specific application should be determined by user
    Comment

    Obinutuzumab is a Type II humanised anti-CD20 monoclonal antibody of the IgG1 subclass derived by humanisation of the parental B-Ly1 mouse antibody and produced in the Chinese Hamster Ovary cell line by recombinant DNA technology

    Protocol
    Research-relevant quantities are available as licence-free consumable as diluted variant. Therapeutic monoclonal antibodies can be used from researchers in in vitro and in vivo experiments.
    Restrictions
    For Research Use only
  • Format
    Liquid
    Concentration
    1 mg/mL
    Buffer
    The dilutant is sterile PBS pH 7.4. No preservatives added
    Preservative
    Without preservative
    Handling Advice
    open only under sterile conditions
    Storage
    4 °C,-20 °C
    Storage Comment
    Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.
    Expiry Date
    36 months
  • Target
    CD20 (MS4A1)
    Alternative Name
    CD20 (MS4A1 Antibody Abstract)
    Synonyms
    B1, Bp35, CD20, CVID5, LEU-16, MS4A2, S7, AA960661, Cd20, Ly-44, Ms4a2, MS4A1, bp35, cd20, ms4a2, leu-16, ms4a4c, cd20-like, membrane spanning 4-domains A1, membrane-spanning 4-domains, subfamily A, member 1, B-lymphocyte antigen CD20, MS4A1, Ms4a1, ms4a1, LOC101694281
    Background
    Synonyms: B1, Bp35, CVID5, LEU-16, MS4A2, S7, AA960661, Cd20, Ly-44, Ms4a2, MS4A1, bp35, cd20, ms4a2, leu-16, ms4a4c, cd20-like
    Molecular Weight
    33 kDa
    Gene ID
    931
    UniProt
    P11836
You are here:
help Support